Thermo Fisher Scientific (TMO) Earnings: Q3 2026 Results and Next Report Date

The quarter ended September 26, 2026 and Thermo Fisher Scientific published the results on October 21, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Thermo Fisher Scientific reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Thermo Fisher acquired Clario Holdings, a provider of endpoint data for clinical trials, on March 24, 2026, and sold its microbiology business to Astorg on August 12, 2026. Acquisitions and divestitures added 3 points to Q3 2026 revenue growth; organic growth was 6%.
• Segment revenues include sales between segments; the Eliminations row reconciles them to consolidated revenues. Thermo Fisher's reported segment figures are rounded, so they sum to $1 million less than the $12,137 million total.

Source: Thermo Fisher Scientific Q3 2026 results, October 21, 2026. Also in the Form 10-Q for the quarter ended September 26, 2026. Figures as reported; checked against the release on November 10, 2026.

How Thermo Fisher Scientific splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Thermo Fisher Scientific's Life Sciences Solutions revenue was $2.7 billion in Q3 2026, up 5% from $2.6 billion in Q3 2025, 22% of total revenue.
• Thermo Fisher Scientific's Analytical Instruments revenue was $2.0 billion in Q3 2026, up 6% from $1.9 billion in Q3 2025, 16% of total revenue.
• Thermo Fisher Scientific's Specialty Diagnostics revenue was $1.1 billion in Q3 2026, down 6% from $1.2 billion in Q3 2025, 9% of total revenue.
• Thermo Fisher Scientific's Laboratory Products and Biopharma Services revenue was $6.9 billion in Q3 2026, up 15% from $6.0 billion in Q3 2025, 57% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenues and diluted EPS, each as first reported in that quarter's release.

Thermo Fisher Scientific's next report is expected around January 28, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q3 2026 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 21, 2026

Laboratory Products and Biopharma Services is Thermo Fisher's largest segment, with $6,863 million of revenue in Q3 2026, or 56.5% of the total before eliminations. Life Sciences Solutions brought in $2,719 million, Analytical Instruments $2,002 million and Specialty Diagnostics $1,098 million, and $546 million of sales between segments were eliminated to reach $12,137 million. (Thermo Fisher Q3 2026 release, Oct 21, 2026)

By type, Thermo Fisher earned $5,384 million from services, $4,870 million from consumables and $1,883 million from instruments in the quarter. Services grew fastest, from $4,633 million a year earlier. Within Laboratory Products and Biopharma Services, clinical research was $2,445 million, pharma services $2,029 million and the research and safety market channel $2,030 million. (Thermo Fisher Form 10-Q, Q3 2026, Oct 30, 2026)

Reported revenue grew 9%, of which acquisitions and divestitures contributed 3 points and currency 0, leaving organic growth of 6%. The clinical research business grew $425 million, primarily from the Clario acquisition, which Thermo Fisher bought on March 24, 2026 for a purchase price of $9,102 million. Specialty Diagnostics revenue fell from $1,174 million, mainly because microbiology, sold to Astorg on August 12, 2026, contributed $70 million against $162 million a year earlier. (Thermo Fisher Q3 2026 release, Oct 21, 2026; Thermo Fisher Form 10-Q, Q3 2026, Oct 30, 2026)

Thermo Fisher's 10-Q describes revenue growth in the pharma and biotech market as very strong in the quarter, the academic and government market as flat, and the industrial and applied market as very strong on demand for high-end instruments. North America contributed $6,266 million of revenue, Europe $3,201 million, Asia-Pacific $2,240 million and other regions $430 million. (Thermo Fisher Form 10-Q, Q3 2026, Oct 30, 2026)

Thermo Fisher had $29.87 billion of remaining performance obligations on open customer contracts at September 26, 2026, with approximately 52% expected to be recognized within twelve months. The longer-dated amounts relate mainly to contract manufacturing, clinical research and extended warranty agreements. (Thermo Fisher Form 10-Q, Q3 2026, Oct 30, 2026)

Thermo Fisher's adjusted EPS of $6.68 was $2.04 above its GAAP diluted EPS of $4.64 in Q3 2026. The largest item excluded is amortization of acquisition-related intangible assets, $1.40 a share, followed by restructuring and other costs at $0.54. Restructuring and other costs over the first nine months include a $72 million gain on the sale of the microbiology business and a $244 million held-for-sale loss. (Thermo Fisher Q3 2026 release, Oct 21, 2026)

GAAP operating margin was 18.6%, against 17.4% a year earlier, and adjusted operating margin was 24.5%, against 23.3%. Thermo Fisher's 10-Q credits very strong productivity improvements, including tariff refunds realized, offset in part by strategic investments. (Thermo Fisher Q3 2026 release, Oct 21, 2026; Thermo Fisher Form 10-Q, Q3 2026, Oct 30, 2026)

Diluted weighted average shares fell to 371 million from 378 million. Thermo Fisher repurchased $4.00 billion of its stock (6.9 million shares) in the first nine months of 2026, and $1.00 billion remained available under its authorization at October 30, 2026. The nine-month effective tax rate was 10.3%, against 7.6% a year earlier. (Thermo Fisher Q3 2026 release, Oct 21, 2026; Thermo Fisher Form 10-Q, Q3 2026, Oct 30, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Thermo Fisher does not state an outlook in its earnings release. The Q3 2026 release says Thermo Fisher would provide updated 2026 financial guidance during its earnings conference call on October 21, 2026, and that it does not provide GAAP financial measures on a forward-looking basis because items such as restructuring, transaction charges and gains or losses on sales of businesses cannot be predicted with reasonable certainty. (Thermo Fisher Q3 2026 release, Oct 21, 2026)

A consensus figure is the average of the models published by the analysts who cover Thermo Fisher Scientific, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Thermo Fisher Scientific's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning TMO is on is TMO a buy or a sell?, what analysts expect next is on the TMO forecast, and what the company does is on the Thermo Fisher Scientific (TMO) stock page.

Every number on this page can be traced to a document Thermo Fisher Scientific published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.